B.Riley Financial Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Maintains Target Price $10
ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) P/S Is Still On The Mark Following 33% Share Price Bounce
Strength Seen in ClearPoint Neuro (CLPT): Can Its 16.9% Jump Turn Into More Strength?
Clinical Laserthermia Systems Gets Additional SEK7.5 Million Orders From ClearPoint Neuro
Express News | Aspen Neuroscience Uses MRI-Guided ClearPoint Navigation System For Patients Enrolled In ASPIRO Phase 1/2a Clinical Trial For Transplantation Of Dopaminergic Neuron Precursor Cells In Patients With Parkinson's Disease
Express News | Clearpoint Neuro Congratulates Partner Aspen Neuroscience on Use of the Clearpoint® Navigation System for All Enrolled Patients in Aspiro Clinical Trial
Express News | Parkinson's Disease Clinical Trial Uses Intraoperative Mri to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
ClearPoint Neuro Announces Full Market Release of SmartFrame OR and ClearPoint PRISM 3T Laser Therapy System
Lake Street Keeps Their Buy Rating on ClearPoint Neuro (CLPT)
We Think Shareholders Are Less Likely To Approve A Pay Rise For ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO For Now
Earnings Call Summary | ClearPoint Neuro(CLPT.US) Q1 2024 Earnings Conference
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2024 Earnings Call Transcript
ClearPoint Neuro: A Strong Buy on Robust Revenue Growth and Strategic Advancements
ClearPoint Neuro, Inc. (CLPT) Q1 2024 Earnings Call Transcript
Express News | ClearPoint Neuro Reaffirms FY24 Revenue $28M-$32M Vs $30.259M Est
ClearPoint Neuro | 10-Q: Quarterly report
ClearPoint Neuro Q1 2024 GAAP EPS $(0.16) Beats $(0.19) Estimate, Sales $7.639M Beat $6.994M Estimate
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, Vs. Street Est of $7M